Long non‑coding RNA MALAT1 serves as an independent
predictive biomarker for the diagnosis, severity and
prognosis of patients with sepsis

Chen,Jianjun; He,Yingfeng; Zhou,Liangliang; Deng,Yijun; Si,Linjie

doi:10.3892/mmr.2020.10923

Long non‑coding RNA MALAT1 serves as an independent predictive biomarker for the diagnosis, severity and prognosis of patients with sepsis

Authors:
- Jianjun Chen
- Yingfeng He
- Liangliang Zhou
- Yijun Deng
- Linjie Si
View Affiliations

Affiliations: Department of Intensive Care Medicine, The First People's Hospital of Yancheng, Yancheng, Jiangsu 224000, P.R. China, Department of Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: January 9, 2020 https://doi.org/10.3892/mmr.2020.10923
Pages: 1365-1373

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present prospective study was conducted to investigate the independent risk and predictive value of plasma long non‑coding RNA metastasis‑associated lung adenocarcinoma transcript 1 (MALAT1) as a biomarker for the diagnosis, severity and prognosis of sepsis. A total of 120 patients with sepsis and 60 healthy controls (HCs) were recruited. The expression levels of plasma MALAT1 were detected by quantitative PCR. The results demonstrated that the plasma levels of MALAT1 were significantly increased in patients with sepsis compared with HCs (P<0.001), in patients with septic shock compared with in patients without septic shock (P<0.001), and in non‑survivors compared with in survivors (P<0.001). MALAT1 plasma levels exhibited weak positive correlation with serum procalcitonin levels (r=0.253; P=0.005), arterial lactate levels (r=0.488; P<0.001), sepsis‑related organ failure assessment scores (r=0.566; P<0.001), and acute physiology and chronic health evaluation II scores (r=0.517; P<0.001) in patients with sepsis. Multivariate logistic regression analysis revealed that high MALAT1 expression was an independent risk factor for sepsis (P<0.001), septic shock (P=0.030) and poor prognosis (P=0.015). In addition, the receiver operating characteristic curve exhibited a significant predictive value for MALAT1 in distinguishing patients with sepsis from HCs with an area under the curve (AUC) of 0.910, patients with septic shock from patients without shock with an AUC of 0.836, and non‑survivors from survivors with an AUC of 0.886. In conclusion, plasma MALAT1 may serve as a biomarker for the diagnosis, severity and prognosis of sepsis.

View Figures

View References

1	Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 43:304–377. 2017. View Article : Google Scholar : PubMed/NCBI
2	Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 315:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
3	Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC and Reinhart K; International Forum of Acute Care Trialists, : Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 193:259–272. 2016. View Article : Google Scholar : PubMed/NCBI
4	Angus DC and van der Poll T: Severe sepsis and septic shock. N Engl J Med. 369:20632013. View Article : Google Scholar : PubMed/NCBI
5	Mira JC, Gentile LF, Mathias BJ, Efron PA, Brakenridge SC, Mohr AM, Moore FA and Moldawer LL: Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit Care Med. 45:253–262. 2017. View Article : Google Scholar : PubMed/NCBI
6	van der Poll T, van de Veerdonk FL, Scicluna BP and Netea MG: The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 17:407–420. 2017. View Article : Google Scholar : PubMed/NCBI
7	Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E and Tomlanovich M; Early Goal-Directed Therapy Collaborative Group, : Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 345:1368–1377. 2001. View Article : Google Scholar : PubMed/NCBI
8	Godinjak A, Iglica A, Rama A, Tančica I, Jusufović S, Ajanović A and Kukuljac A: Predictive value of SAPS II and APACHE II scoring systems for patient outcome in a medical intensive care unit. Acta Med Acad. 45:97–103. 2016.PubMed/NCBI
9	Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et al: The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
12	Zhang X, Hamblin MH and Yin KJ: The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol. 14:1705–1714. 2017. View Article : Google Scholar : PubMed/NCBI
13	Lipovich L, Dachet F, Cai J, Bagla S, Balan K, Jia H and Loeb JA: Activity-dependent human brain coding/noncoding gene regulatory networks. Genetics. 192:1133–1148. 2012. View Article : Google Scholar : PubMed/NCBI
14	Watts R, Johnsen VL, Shearer J and Hittel DS: Myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis. Am J Physiol Cell Physiol. 304:C995–C1001. 2013. View Article : Google Scholar : PubMed/NCBI
15	Michalik KM, You X, Manavski Y, Doddaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, et al: Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 114:1389–1397. 2014. View Article : Google Scholar : PubMed/NCBI
16	Yoshimoto R, Mayeda A, Yoshida M and Nakagawa S: MALAT1 long non-coding RNA in cancer. Biochim Biophys Acta. 1859:192–199. 2016. View Article : Google Scholar : PubMed/NCBI
17	Uchida S and Dimmeler S: Long noncoding RNAs in cardiovascular diseases. Circ Res. 116:737–750. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zhang X, Tang X, Liu K, Hamblin MH and Yin KJ: Long noncoding RNA malat1 regulates cerebrovascular pathologies in ischemic stroke. J Neurosci. 37:1797–1806. 2017. View Article : Google Scholar : PubMed/NCBI
19	Vergadi E, Vaporidi K and Tsatsanis C: Regulation of endotoxin tolerance and compensatory anti-inflammatory response syndrome by Non-coding RNAs. Front Immunol. 9:27052018. View Article : Google Scholar : PubMed/NCBI
20	Yang H, Liang N, Wang M, Fei Y, Sun J, Li Z, Xu Y, Guo C, Cao Z, Li S and Jiao Y: Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus. Oncotarget. 8:77400–77406. 2017.PubMed/NCBI
21	Shaker OG, Mahmoud RH, Abdelaleem OO, Ibrahem EG, Mohamed AA, Zaki OM, Abdelghaffar NK, Ahmed TI, Hemeda NF, Ahmed NA and Mansour DF: LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis. Biosci Rep. 39:BSR201813352019. View Article : Google Scholar : PubMed/NCBI
22	Pan F, Zhu L, Lv H and Pei C: Quercetin promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by upregulating lncRNA MALAT1. Int J Mol Med. 38:1507–1514. 2016. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K and Akimitsu N: MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 584:4575–4580. 2010. View Article : Google Scholar : PubMed/NCBI
25	Huang C, Han J, Wu Y, Li S, Wang Q, Lin W and Zhu J: Exosomal MALAT1 derived from oxidized low-density lipoprotein-treated endothelial cells promotes M2 macrophage polarization. Mol Med Rep. 18:509–515. 2018.PubMed/NCBI
26	Gao F, Chen R, Xi Y, Zhao Q and Gao H: Long noncoding RNA MALAT1 regulates sepsis in patients with burns by modulating miR-214 with TLR5. Mol Med Rep. 19:3756–3766. 2019.PubMed/NCBI
27	Shaker OG, Abdelaleem OO, Mahmoud RH, Abdelghaffar NK, Ahmed TI, Said OM and Zaki OM: Diagnostic and prognostic role of serum miR-20b, miR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy. IUBMB Life. 71:310–320. 2019. View Article : Google Scholar : PubMed/NCBI
28	Zhang B, Arun G, Mao YS, Lazar Z, Hung G, Bhattacharjee G, Xiao X, Booth CJ, Wu J, Zhang C and Spector DL: The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2:111–123. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chen H, Wang X, Yan X, Cheng X, He X and Zheng W: LncRNA MALAT1 regulates sepsis-induced cardiac inflammation and dysfunction via interaction with miR-125b and p38 MAPK/NFkB. Int Immunopharmacol. 55:69–76. 2018. View Article : Google Scholar : PubMed/NCBI
30	Yu Z, Rayile A, Zhang X, Li Y and Zhao Q: Ulinastatin protects against lipopolysaccharide-induced cardiac microvascular endothelial cell dysfunction via downregulation of lncRNA MALAT1 and EZH2 in sepsis. Int J Mol Med. 39:1269–1276. 2017. View Article : Google Scholar : PubMed/NCBI
31	Dai L, Zhang G, Cheng Z, Wang X, Jia L, Jing X, Wang H, Zhang R, Liu M, Jiang T, et al: Knockdown of LncRNA MALAT1 contributes to the suppression of inflammatory responses by up-regulating miR-146a in LPS-induced acute lung injury. Connect Tissue Res. 59:581–592. 2018. View Article : Google Scholar : PubMed/NCBI
32	Ding Y, Guo F, Zhu T, Li J, Gu D, Jiang W, Lu Y and Zhou D: Mechanism of long non-coding RNA MALAT1 in lipopolysaccharide-induced acute kidney injury is mediated by the miR-146a/NF-κB signaling pathway. Int J Mol Med. 41:446–454. 2018.PubMed/NCBI
33	Pan L, Liu D, Zhao L, Wang L, Xin M and Li X: Long noncoding RNA MALAT1 alleviates lipopolysaccharide-induced inflammatory injury by upregulating microRNA-19b in murine chondrogenic ATDC5 cells. J Cell Biochem. 119:10165–10175. 2018. View Article : Google Scholar : PubMed/NCBI
34	Gast M, Rauch BH, Nakagawa S, Haghikia A, Jasina A, Haas J, Nath N, Jensen L, Stroux A, Böhm A, et al: Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE-/-mice. Cardiovasc Res. 115:302–314. 2019. View Article : Google Scholar : PubMed/NCBI
35	Zhao G, Su Z, Song D, Mao Y and Mao X: The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-κB. FEBS Lett. 590:2884–2895. 2016. View Article : Google Scholar : PubMed/NCBI
36	Castelli GP, Pognani C, Cita M, Stuani A, Sgarbi L and Paladini R: Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: Diagnosis and monitoring of sepsis. Minerva Anestesiol. 72:69–80. 2006.PubMed/NCBI
37	Dahaba AA and Metzler H: Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol. 75:447–452. 2009.PubMed/NCBI
38	Tian X and Xu G: Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: Systematic review and meta-analysis. BMJ Open. 5:e0086532015. View Article : Google Scholar : PubMed/NCBI
39	Zeng Q, Wu J and Yang S: Circulating lncRNA ITSN1-2 is upregulated, and its high expression correlates with increased disease severity, elevated inflammation, and poor survival in sepsis patients. J Clin Lab Anal. 33:e228362019. View Article : Google Scholar : PubMed/NCBI
40	Huang Q, Huang C, Luo Y, He F and Zhang R: Circulating lncRNA NEAT1 correlates with increased risk, elevated severity and unfavorable prognosis in sepsis patients. Am J Emerg Med. 36:1659–1663. 2018. View Article : Google Scholar : PubMed/NCBI
41	American college of chest physicians/society of critical care medicine consensus conference, . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 20:864–874. 1992. View Article : Google Scholar : PubMed/NCBI